Can Delayed CEM Improve Residual Breast Cancer Detection?

Introduction to Response Assessment in Breast Cancer

Monitoring treatment response remains a critical challenge for oncologists managing breast cancer in India. Recently, contrast-enhanced mammography protocols have emerged as a robust tool for evaluating residual disease after neoadjuvant chemotherapy. This advanced imaging technique combines anatomical precision with functional vascular assessment. Consequently, it provides clinicians with detailed information regarding the tumor’s response to systemic therapy. Accurate identification of residual disease helps in planning precise surgical interventions. Moreover, it assists in determining the necessity for further adjuvant treatments.

Optimizing Contrast-Enhanced Mammography Protocols for Clinical Accuracy

New research indicates that the timing of image acquisition significantly impacts diagnostic performance. Specifically, delayed and combined contrast-enhanced mammography protocols demonstrate superior sensitivity compared to early-phase imaging alone. In a recent study involving over 200 women, the delayed protocol achieved a sensitivity of 85.7% for detecting residual disease. In contrast, the early protocol only reached 68.1% sensitivity. Therefore, incorporating a delayed phase into the imaging workflow allows radiologists to capture subtle enhancement patterns. These patterns often indicate lingering malignant tissue that early images might miss.

Clinical Implications for Surgical Planning

Achieving clear surgical margins is vital for successful breast-conserving surgery. The study results show that measurements from combined imaging protocols correlate closely with pathological tumor staging. Furthermore, the negative predictive value of these protocols is exceptionally high. This high accuracy gives surgeons greater confidence when predicting a pathological complete response. As a result, patients may avoid more extensive and invasive surgeries like mastectomies. Additionally, CEM serves as a cost-effective and accessible alternative to MRI in many Indian clinical settings.

Conclusion

Optimizing the timing of contrast acquisition is essential for accurate post-chemotherapy evaluation. By utilizing delayed imaging, healthcare providers can improve the detection of residual breast cancer. This shift in practice supports better clinical outcomes and personalized surgical management for patients. Physicians should consider standardizing these protocols to ensure the highest level of diagnostic reliability.

Frequently Asked Questions

Q1: Why are delayed acquisitions more sensitive for detecting residual disease?

Delayed acquisitions allow the contrast agent more time to accumulate within residual tumor tissues. This timing helps highlight subtle vascular changes that are not immediately visible during the early phase of the examination.

Q2: How does contrast-enhanced mammography compare with MRI for monitoring chemotherapy?

CEM offers diagnostic performance comparable to MRI for assessing residual tumor size. However, CEM is generally faster, more accessible, and more cost-effective, making it a viable alternative for many patients.

References

1. Bellini C et al. Early, delayed, or combined contrast-enhanced mammography for detecting residual disease after neoadjuvant chemotherapy in breast cancer. Eur Radiol. 2026 May 15. doi: 10.1007/s00330-026-12633-1. PMID: 42141291.
2. Trimboli RM et al. Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer. AJR Am J Roentgenol. 2022;219(3):393-401.
3. Bhimani SS et al. Contrast-enhanced mammography: clinical applications and imaging findings. Radiographics. 2022;42(1):E1-E18.

“